{
    "clinical_study": {
        "@rank": "8212", 
        "acronym": "SPRINT", 
        "arm_group": [
            {
                "arm_group_label": "BG00010 administered as an IV injection at various dose levels", 
                "arm_group_type": "Experimental", 
                "description": "BG00010 administered as an IV injection at various dose levels 3 times per week for 1 week"
            }, 
            {
                "arm_group_label": "Placebo Dose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "doses of placebo Intravenous (IV) injection 3 times per week for 1 week"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to assess the efficacy of Intravenous (IV) BG00010\n      (Neublastin) in improving pain in painful lumbar radiculopathy subjects when administered 3\n      times per week for 1 week.\n\n      The secondary objectives of this study in this study population are as follows: To explore\n      the duration of the effect of BG00010 in improving pain; To explore the dose response curve\n      on pain reduction; To assess the safety and tolerability of BG00010; To assess the serum\n      exposure to BG00010.\n\n      During the study, frequent assessment of allocation probability will be conducted to guide\n      subsequent randomization of subjects into dose groups."
        }, 
        "brief_title": "BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Subjects With Painful Lumbar Radiculopathy", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Painful Lumbar Radiculopathy", 
            "Sciatica", 
            "Radiculopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pain", 
                "Sciatica", 
                "Radiculopathy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Body weight \u2264133 kg.\n\n          -  Leg pain radiating, diagnosed as being due to painful lumbar radiculopathy or\n             lumbosacral radiculopathy, the diagnosis of which occurred within \u22656 months and \u22645\n             years of the time of randomization.\n\n          -  Objective, documented evidence of painful lumbar radiculopathy involvement\n\n          -  Lower back pain\n\n          -  Leg pain\n\n          -  Male and female subjects of childbearing potential must practice effective\n             contraception during the study and be willing and able to continue contraception for\n             3 months after their last dose of study treatment.\n\n        KEY Exclusion Criteria:\n\n          -  History of or positive test result at screening for human immunodeficiency virus, or\n             for hepatitis C virus antibody, or current Hepatitis B infection.\n\n          -  Clinically significant diseases or conditions as determined by the investigator.\n\n          -  Major surgery within 30 days prior to the Screening Visit or that is scheduled to\n             occur during the study.\n\n          -  Previous participation in a study with neurotrophic factors (e.g., nerve growth\n             factor).\n\n          -  Participation in a study with another investigational drug or approved therapy for\n             investigational use within 3 months prior to Day 1.\n\n          -  Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec\n             Inc. (Biogen Idec), make the subject unsuitable for enrollment\n\n        NOTE:  Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "165", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873404", 
            "org_study_id": "103NS201"
        }, 
        "intervention": [
            {
                "arm_group_label": "BG00010 administered as an IV injection at various dose levels", 
                "description": "BG00010 administered as an IV injection at various dose levels 3 times per week for 1 week", 
                "intervention_name": "BG00010", 
                "intervention_type": "Drug", 
                "other_name": "Neublastin"
            }, 
            {
                "arm_group_label": "Placebo Dose", 
                "description": "doses of placebo Intravenous (IV) injection 3 times per week for 1 week", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85018"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93710"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91105"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hileah", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33013"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32232"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31904"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60657"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evansville", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47714"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66210"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40503"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02135"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14618"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27103"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84106"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec Investigator"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change from Baseline in the mean 24-hour average general pain intensity (AGPI) score", 
            "safety_issue": "No", 
            "time_frame": "At the end of treatment period (Day 6-10)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in the mean 24-hour average back pain intensity (ABPI) score", 
                "safety_issue": "No", 
                "time_frame": "At the end of the treatment period (day 6-10)"
            }, 
            {
                "measure": "Change from Baseline in the mean 24-hour average leg pain intensity score (ALPI)", 
                "safety_issue": "No", 
                "time_frame": "At the end of the treatment period (day 6-10)"
            }, 
            {
                "measure": "Change from Baseline in the individual mean 24-hour average general pain intensity (AGPI)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 5"
            }, 
            {
                "measure": "Change from Baseline in the individual mean 24-hour average back pain intensity (ABPI)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 5"
            }, 
            {
                "measure": "Change from Baseline in the individual mean 24-hour average leg pain intensity (ALPI)", 
                "safety_issue": "No", 
                "time_frame": "Up to week 5"
            }, 
            {
                "measure": "Maximum observed serum concentration (Cmax) of BG00010", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 5"
            }, 
            {
                "measure": "Number of subjects with adverse events (AEs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to week 9"
            }, 
            {
                "measure": "Change from Baseline in Incidence of neutralizing antibodies in serum", 
                "safety_issue": "Yes", 
                "time_frame": "Up to week 9"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}